Using organoids derived from patients with RCC, Hamdan F et al. reported that an oncolytic adenovirus secreting the cross-hybrid Fc-fusion peptide that binds to programmed death-ligand 1 (PD-L1) and activates the Fc-effector significantly increases tumor killing and minimizes toxicity compared with the PD-L1 inhibitor atezolizumab, IgG1-PDL1 and IgA-PDL1 [119]. This evidence concerns the gene CD274 and neoplasm.